Topics

FDA grants Breakthrough Therapy designation for NSCLC drug tepotinib

06:02 EDT 12 Sep 2019 | SmartBrief

Merck's investigational treatment tepotinib received Breakthrough Therapy Designation from the FDA to treat metastatic non-sm -More

Original Article: FDA grants Breakthrough Therapy designation for NSCLC drug tepotinib

NEXT ARTICLE

More From BioPortfolio on "FDA grants Breakthrough Therapy designation for NSCLC drug tepotinib"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...